Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND
SHANGHAI, July 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National...